STOCK TITAN
  1. Home
  2. Sec-filings
  3. IXHL
  4. [8-K] Incannex Healthcare Limited American Reports Material Event

Leading Sleep Expert Joins Incannex's Advisory Board to Advance Sleep Apnea Treatment

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Incannex Healthcare (NASDAQ: IXHL), an emerging growth company, announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board on June 24, 2025, specifically to support its Obstructive Sleep Apnea program.

Key details from the 8-K filing:

  • The company is listed on The Nasdaq Stock Market with common stock at $0.0001 par value per share
  • Headquartered in Norwest, NSW, Australia
  • Joel Latham serves as Chief Executive Officer and President
  • The company has elected emerging growth company status
  • The appointment represents a strategic expansion of expertise in sleep medicine, potentially strengthening the company's clinical development programs

This strategic addition to the advisory board signals Incannex's continued focus on advancing its sleep apnea therapeutic programs and enhancing its clinical development capabilities.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

Why did IXHL file an 8-K on June 24, 2025?
IXHL filed an 8-K to announce the expansion of its Clinical Advisory Board with the appointment of Dr. Douglas B. Kirsch to support their Obstructive Sleep Apnea Program.

Who is the new appointee to IXHL's Clinical Advisory Board?
Dr. Douglas B. Kirsch was appointed to IXHL's Clinical Advisory Board to support the company's Obstructive Sleep Apnea Program, as announced on June 24, 2025.

Who is the current CEO of IXHL?
Joel Latham serves as the Chief Executive Officer and President of Incannex Healthcare Inc. (IXHL), as evidenced by his signature on the 8-K filing dated June 24, 2025.

Is IXHL considered an emerging growth company?
Yes, IXHL is classified as an emerging growth company as indicated by the checked box in the 8-K filing. The company has not elected to use the extended transition period for complying with new financial accounting standards.

Where is IXHL's principal executive office located?
IXHL's principal executive office is located at Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia.
false 0001873875 0001873875 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 24, 2025

 

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41106   93-2403210

(State or other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

Suite 105, 8 Century Circuit Norwest,

NSW 2153 Australia

   Not applicable
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, including Area Code: +61 409 840 786

 

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
Common Stock, $0.0001 par value per share   IXHL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

  

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

On June 24, 2025, Incannex Healthcare Inc. Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release of Incannex Healthcare Inc., dated June 24, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Incannex Healthcare Inc.
     
Date: June 24, 2025   /s/ Joel Latham
  Name:  Joel Latham
  Title: Chief Executive Officer and President

 

2

 

Source: View Original Filing on SEC EDGAR